STOCK TITAN

Adial Pharmaceuticals Inc - ADIL STOCK NEWS

Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.

Overview

Adial Pharmaceuticals Inc (symbol: ADIL) is a clinical-stage biopharmaceutical company dedicated to developing personalized therapies for addiction and related disorders. Leveraging advanced pharmacogenomics, precision medicine, and cutting-edge clinical research methodologies, the company is focused on transforming how alcohol use disorder (AUD) and other addictive conditions are treated.

Core Business and Value Proposition

At its core, Adial Pharmaceuticals is committed to the development of prescription medications that address the underlying issues of addiction. The company’s lead investigational candidate, AD04, is a genetically targeted, serotonin-3 receptor antagonist engineered specifically for individuals suffering from alcohol use disorder. By utilizing a companion diagnostic test to identify patients with distinct genetic markers, Adial offers a personalized approach that has the potential to significantly enhance treatment outcomes compared to traditional therapies.

Scientific and Clinical Approach

Adial’s scientific methodology is built on extensive pharmacological research and a deep understanding of pharmacogenomics. The company conducts detailed pharmacokinetic and dose-range studies to ensure that its investigational products, including AD04, achieve optimal bioavailability and safety profiles. A series of clinical studies have evaluated the effects of food on drug absorption, dose proportionality, and the overall pharmacokinetic performance of AD04, thus informing precise study designs that cater to genetically defined patient groups.

Research and Development

The research and development (R&D) efforts at Adial are characterized by a thorough and systematic approach to drug development. While the pipeline includes drug candidates targeting various forms of addiction, the emphasis remains on alcohol abuse. The company’s use of pharmacogenomic information to tailor treatments sets it apart, as clinical studies focus on patients with specific single nucleotide polymorphisms (SNPs) that influence the binding and effectiveness of AD04 at the serotonin-3 receptor. This bespoke approach underscores a commitment to patient-specific therapies that combine innovative science with rigorous clinical evaluation.

Operational Excellence and Regulatory Strategy

Operationally, Adial Pharmaceuticals adheres to strict regulatory standards and leverages an operational framework that emphasizes efficiency and precision. The company pursues a 505(b)(2) regulatory pathway, which allows it to integrate existing data on similar compounds while focusing on its novel, genetically targeted approach. By maintaining transparent communication with regulatory bodies and conducting meticulously designed studies, Adial positions itself to meet the stringent requirements necessary for eventual market approval.

Competitive Landscape and Market Position

In a competitive biopharmaceutical arena, Adial differentiates itself by focusing on a niche segment of the market: personalized treatments for addiction. Unlike traditional approaches, which often deploy a generalized strategy, Adial uses companion diagnostic tests to pinpoint genetic markers that predict a patient’s response to treatment. This specialized approach not only enhances the therapeutic efficacy of its products but also provides a clear competitive advantage in an industry that increasingly values precision medicine and tailored treatment protocols.

Technological Capabilities and Intellectual Property

Adial Pharmaceuticals has built a solid foundation of technological expertise, with a focus on molecular genetics and advanced diagnostic tools. The company’s expanding patent portfolio protects its unique approach to diagnosing and potentially treating addiction. Its integrated platform, which combines genetic testing with clinical pharmacology, allows for the identification of patient subgroups most likely to benefit from AD04. This intellectual property strategy not only secures the company’s innovative methods but also reinforces its commitment to developing personalized, scientifically validated therapies.

Scientific Innovation and Industry Impact

Innovation is central to Adial’s mission. By targeting the serotonin-3 receptor—a key player in the neurochemical pathways associated with addiction—the company is pioneering a new paradigm in the treatment of AUD. The integration of detailed genetic profiles through companion diagnostic tests demonstrates how modern biotechnology can be harnessed to solve complex medical challenges. These innovations have the potential to set new standards in the field of addiction medicine, impacting both clinical practice and future research directions.

Commitment to Transparency and Data-Driven Approaches

Every stage of Adial’s product development is marked by a steadfast commitment to transparency and a data-driven approach. Whether it is the execution of pharmacokinetic studies or the rigorous analysis of genetic biomarkers, the company ensures that its clinical evidence is robust and clearly communicated. This commitment not only builds trust among investors and healthcare professionals but also underscores the company’s expertise in tailoring treatment strategies based on verifiable scientific data.

Integrated Development and Cross-Disciplinary Expertise

Adial Pharmaceuticals integrates expertise from multiple scientific and medical disciplines, including pharmacology, molecular biology, and clinical research. This cross-disciplinary collaboration empowers the company to translate complex scientific insights into practical, patient-focused therapies. By actively engaging with clinical research organizations, academic institutions, and regulatory agencies, Adial ensures that its strategies are both innovative and aligned with the highest industry standards.

Strategic Vision in a Niche Market

In a marketplace crowded with traditional pharmaceuticals, Adial Pharmaceuticals has carved out a niche based on customized approaches to treating addiction. Its precise focus on patients with distinct genetic profiles allows it to offer unique therapeutic options that address the underlying mechanisms of addiction. This strategy not only enhances the clinical relevance of its products but also aligns with broader trends in personalized medicine, ensuring that the company remains at the forefront of therapeutic innovation.

Conclusion

Adial Pharmaceuticals Inc exemplifies a transformative approach to treating addiction through the integration of advanced pharmacogenomics, rigorous clinical research, and personalized treatment methodologies. The company’s focus on effectively addressing alcohol use disorder and other addictive behaviors with targeted therapies positions it as a knowledgeable and specialized entity within the biopharmaceutical industry. By continually refining its clinical strategies and leveraging comprehensive diagnostic tools, Adial reinforces its commitment to precision medicine and offers a detailed, evidence-based framework that informs and inspires the future of addiction treatment.

Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL) has received a Notice of Allowance from the United States Patent and Trademark Office for a new patent. This patent will expand Adial's intellectual property protection for its lead investigational drug, AD04, designed to treat alcohol use disorder (AUD). The patent covers additional genotype combinations identified through the Company's proprietary genetic diagnostic tool, enhancing AD04's precision medicine approach.

Cary Claiborne, CEO of Adial Pharmaceuticals, stated that this milestone broadens their patent estate and provides greater flexibility in advancing AD04. He emphasized the company's commitment to delivering innovative, genetically-targeted treatments for addiction. The patent notification reinforces Adial's focus on using cutting-edge science to develop more effective treatments with fewer side effects for those affected by addiction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
none
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL) commends the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for its updated definition of recovery, which now includes non-abstinence solutions. This aligns with Adial's AD04 program for alcohol use disorder (AUD), which offers patients flexibility in reducing drinking and/or achieving abstinence.

The NIAAA's new definition, emphasized in its 2025 Professional Judgement Budget, recognizes that effective recovery solutions can focus on harm reduction and improved quality of life. This shift validates Adial's approach and potentially broadens its commercial and government market potential.

Cary Claiborne, CEO of Adial Pharmaceuticals, stated that AD04 is uniquely positioned to provide a therapeutic option for those seeking reduction in alcohol use or complete abstinence. The company is optimistic that NIAAA's new perspective will stimulate additional support for programs like AD04 in both commercial and government sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL) has announced the database lock for its pharmacokinetics study of AD04, the company's lead investigational treatment for Alcohol Use Disorder (AUD) in heavy drinking patients. The study, which enrolled 30 healthy adult volunteers, compared the pharmacokinetic profile of AD04 at a 0.33 mg oral dose, with or without food, against a reference standard product.

Topline results are expected in the fourth quarter of 2024. The data has been transferred to independent statisticians for analysis, which will inform Adial's next FDA interaction and help shape the clinical strategy for the upcoming Phase 3 study. The company believes these results will strengthen its position for potential strategic collaborations and future clinical development of AD04.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on addiction treatment therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.

CEO Cary Claiborne will represent Adial at the conference. The company's presentation will be available on-demand to registered attendees starting September 9, 2024, at 7:00 AM Eastern Time. Investors can access the presentation webcast through the conference platform or Adial's investor relations website.

Additionally, Adial's management team will be conducting one-on-one meetings with qualified investors throughout the conference. Interested parties can request meetings by contacting adil@crescendo-ir.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
conferences
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL) reported its Q2 2024 financial results and provided a business update. Key highlights include:

1. Initiated a pharmacokinetics study of AD04, their lead investigational drug for Alcohol Use Disorder (AUD), with topline results expected in Q4 2024.

2. Collaborated with Boudicca Dx to develop a companion diagnostic genetic test for AD04.

3. Filed a new patent application extending intellectual property protection to 2044.

4. Published two peer-reviewed articles supporting AD04's potential efficacy and safety profile.

5. Cash and cash equivalents were $3.3 million as of June 30, 2024.

6. Net loss was $2.5 million for Q2 2024, compared to a net income of $1.1 million in Q2 2023.

7. R&D expenses increased by $583,000 and G&A expenses increased by $228,000 compared to Q2 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL) has partnered with Boudicca Dx to advance the regulatory strategy for its companion diagnostic genetic test. This test is designed to accompany AD04, Adial's lead investigational asset for Alcohol Use Disorder (AUD) treatment. Boudicca Dx will support Adial in ensuring the test's compliance with FDA guidelines, a important step in Adial's regulatory strategy and preparation for its planned Phase 3 program.

The collaboration aims to validate the companion diagnostic both technically and clinically, supporting patient identification and recruitment for AD04 trials. This partnership is seen as a key component in Adial's mission to develop a first-in-class precision medicine for AUD treatment, addressing a significant unmet need in a disease affecting over 30 million people in the US and causing 3 million deaths worldwide annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL) has announced the completion of patient dosing in the pharmacokinetics study of AD04, their lead investigational treatment for Alcohol Use Disorder (AUD). The study, involving 30 healthy adult volunteers, aims to optimize dosing and enhance efficacy and safety for AUD patients. Topline results are expected in the fourth quarter of 2024.

The single-center open-label study compares the pharmacokinetic profile of AD04 at a 0.33 mg oral dose, with or without food, against a reference standard. This milestone brings Adial closer to initiating their Phase 3 clinical trial and supports ongoing partnership discussions. The company plans to review the data thoroughly and engage with the FDA to align their development plan with regulatory expectations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL) has filed a new patent application for AD04, its lead investigational therapeutic agent for Alcohol Use Disorder (AUD) in heavy drinking patients. The patent, if granted, is expected to protect Adial's core assets until at least 2044. This application follows an extensive review of data and information, initiated after the company hired new patent counsel to strengthen its intellectual property portfolio.

AD04 is a genetically targeted, serotonin-3 receptor antagonist designed to treat AUD in patients consuming 10 or more drinks per drinking day. The company is currently advancing the AD04 program with ongoing pharmacokinetics studies. CEO Cary Claiborne emphasized the importance of this patent application in extending protection for Adial's core assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL) has advanced to the second cohort in its pharmacokinetics study of AD04, a genetically targeted therapeutic agent for Alcohol Use Disorder (AUD). The study, initiated in June 2024, is expected to conclude in Q4 2024 with topline results from both cohorts. This single-center, open-label study will enroll up to 30 healthy adult volunteers to compare the pharmacokinetic profile of AD04 when administered as an oral dose of 0.33 mg with or without food against a reference standard product.

CEO Cary Claiborne expressed satisfaction with the study's progress, noting that the results will provide important insights for designing their upcoming Phase 3 Clinical Trial. Adial plans to engage with the FDA after receiving the topline data to seek feedback on their Phase 3 program design.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.58%
Tags
none
Rhea-AI Summary

Adial Pharmaceuticals has announced the publication of results from its Phase 3 ONWARD study in the European Journal of Internal Medicine. The study focuses on AD04, a precision medicine for treating Alcohol Use Disorder (AUD) in patients with specific genetic profiles. Results show AD04 significantly reduces heavy drinking days after six months compared to a placebo in patients with certain genotypes. AD04's adverse events (AEs) are similar to those of a placebo, highlighting its safety. Additionally, combining AD04 with psychosocial interventions may increase treatment uptake among AUD patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.39%
Tags
none

FAQ

What is the current stock price of Adial Pharmaceuticals (ADIL)?

The current stock price of Adial Pharmaceuticals (ADIL) is $0.656 as of April 1, 2025.

What is the market cap of Adial Pharmaceuticals (ADIL)?

The market cap of Adial Pharmaceuticals (ADIL) is approximately 4.2M.

What is the core focus of Adial Pharmaceuticals?

Adial Pharmaceuticals is focused on developing personalized therapies for addiction and related disorders, with a particular emphasis on treating alcohol use disorder using advanced pharmacogenomic approaches.

How does AD04 work?

AD04 is a genetically targeted, serotonin-3 receptor antagonist designed to reduce alcohol cravings by targeting specific genetic markers identifiable through companion diagnostic tests.

What differentiates Adial from other pharmaceutical companies in the addiction treatment space?

Adial differentiates itself by combining precision medicine with rigorous pharmacogenomic research, allowing for treatments tailored to individual genetic profiles, which enhances therapeutic efficacy and safety.

How does Adial leverage pharmacogenomics in its treatment approach?

The company utilizes companion diagnostic tests to identify patients with specific genetic mutations, ensuring that therapies like AD04 are administered to those most likely to benefit, thereby personalizing treatment strategies.

What therapeutic areas does Adial focus on?

While Adial primarily targets alcohol use disorder, its investigational product AD04 also shows potential for treating other addictive disorders such as opioid use disorder, gambling, and obesity.

What is the significance of the 505(b)(2) regulatory pathway for Adial?

The 505(b)(2) pathway enables Adial to leverage existing data on similar compounds while focusing on its novel, genetically targeted treatment approach, streamlining the path towards regulatory approval.

How does Adial ensure the safety and efficacy of its investigational products?

Adial conducts comprehensive pharmacokinetic and dose proportionality studies, along with rigorous clinical trials, to confirm the safety, tolerability, and optimal efficacy of its products such as AD04.

How is Adial building its competitive advantage?

By focusing on a personalized, evidence-based treatment model that targets genetically defined subgroups, and by developing robust intellectual property, Adial maintains a distinct competitive edge in the biopharmaceutical market.
Adial Pharmaceuticals Inc

Nasdaq:ADIL

ADIL Rankings

ADIL Stock Data

4.20M
6.46M
1.75%
9.58%
10.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHARLOTTESVILLE